7 Results for "

Nectin-4 ADC

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Nectin-4 ADC" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-P99016
CAS No.: 1448664-46-7

Target:  

ADC Antibodies Nectin-4

Research Areas:  

Cancer

Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99016B
CAS No.: 1346452-25-2

Research Areas:  

Cancer

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99016A
CAS No.: 1346452-25-2
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
loading...
    loading...
Cat. No.: HY-147271
CAS No.: 2679821-39-5
Purity:  99.48%
Research Areas:  

Others

Mal-PEG8-Val-Ala-PAB-Exatecan (Compound 9b) is an antibody-drug conjugate linker (ADC linker) that binds to Nectin-4 polypeptides conjugated to chemotherapeutic agents. Mal-PEG8-Val-Ala-PAB-Exatecan can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P991742
Synonyms: 15A7.5; ETx-22 Antibody

Target:  

ADC Antibodies

Research Areas:  

Cancer

LY4101174 Antibody (15A7.5; ETx-22 Antibody) is an ADC antibody that serves as the antibody component of LY4101174. LY4101174 is an antibody-drug conjugate (ADC) targeting nectin-4 and exhibits broad-spectrum anti-tumor activity. LY4101174 Antibody is applicable to research related to solid tumors .
loading...
    loading...
Cat. No.: HY-P992133
CAS No.: 3049680-24-9
Synonyms: SYS6002 Antibody; CRB-701 Antibody

Target:  

ADC Antibodies Nectin-4

Research Areas:  

Cancer

Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P99016C
CAS No.: 1448664-46-7

Target:  

ADC Antibodies Nectin-4

Research Areas:  

Cancer

Enfortumab (powder) is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody agent conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab (powder) can be used for the study of locally advanced and metastatic urothelial carcinoma .
loading...
    loading...